Drug Profile
RQ 00433412
Alternative Names: RQ-00433412Latest Information Update: 18 Nov 2022
Price :
$50
*
At a glance
- Originator RaQualia Pharma
- Class Laxatives; Small molecules
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Anorexia; Cachexia; Constipation
Most Recent Events
- 01 Nov 2022 Preclinical studies is ongoing in Cachexia in Japan (PO) as of November 2022 (Raqualia Pharma pipeline, November 2022
- 01 Nov 2022 Preclinical studies is ongoing in Anorexia in Japan (PO) as of November 2022 (Raqualia Pharma pipeline, November 2022
- 28 May 2022 No recent reports of development identified for preclinical development in Anorexia in Japan (PO)